25 February 2020

Shenzhen Kangtai wins nod for Hepatitis B vaccine, paper says

Shenzhen Kangtai Biological Products Co. Ltd. has received a new Good Manufacturing Practice (GMP) certificate for its drug production lines, the 21st Century Business Herald reported Monday, citing a company statement. In November 2013, a series of infant deaths fueled rumors linking the cases to the injection of Hepatitis B vaccine, but the China Food and Drug Administration issued a statement on Jan. 3 that 17 out of the 18 suspected cases were unrelated to vaccine injections, sweeping aside public fears on using the drug. According to media reports, Shenzhen Kangtai has suffered a revenue loss of over 200 million yuan (US$25.77 million) from crisis, the report said.

– Contact HKEJ at [email protected]